VR Logo

Cybin Inc. (CYBN) download report


Healthcare | Biotechnology & Pharma Research

Cybin Inc. (CYBN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders.

IPO Date: 13-Sep-2019

Co-Founder, Pres & Exec. Chairman: Mr. Eric So L.L.B., LLB

Chief Exec. Officer: Mr. Douglas L. Drysdale

Listing: NYSE: CYBN

Country: Canada

Headquarters: Toronto, ON

Website: https://www.cybin.com

Key Facts

Market cap: $100.38 Mln

Revenue (TTM): CA$0.00 Mln

Earnings (TTM): CA$-63.31 Mln

Cash: CA$63.58 Mln

Total Debt: CA$0.00 Mln

Insider's Holding: 22.40%

Liquidity: Low

52 Week range: $0.39 - 3.38

Shares outstanding: 163,220,992

Stock Performance

Time Period Cybin (CYBN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-51.83-8.97-18.40
1 month-10.66-3.38-8.42
3 months-21.36-7.93-14.06
1 Year-73.850.55-17.64
3 Years--10.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Cybin (CYBN) S&P Small-Cap 600 S&P BSE Sensex
2021-19.4625.2721.99